Sign In
Buy EDIT
$2.78
-0.0400 (-1.42%)
At Close: Jun 03, 2026
CAMBRIDGE, Mass., June 12, 2020 -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced results from a pre-clinical, proof-of-concept study.
The Daily Biotech Pulse: FDA Nod For Viela, 3 IPOs And Hematology Congress Presentations
12:00am, Friday, 12'th Jun 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 11)
ADC Therapeutics SA (NYSE:...
CRISPR Market Analysis By Industry Growth, Size, Share, Demand, Trends and Research Report
11:19am, Thursday, 11'th Jun 2020
Jun 11, 2020 (AmericaNewsHour) --
Global CRISPR Market Size Study by Application(Genome Editing, Genetic Engineering, Gene Library, CRISPR Plasmid, Human...
Xconomy: Verve Therapeutics Adds $63M to Edit Heart Attack Risk Out of Genes
10:00am, Thursday, 11'th Jun 2020
Verve Therapeutics aims to use gene editing to address heart attacks by targeting the liver, not the heart. And it wants to make its edits inside the
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2020 Update
02:39pm, Monday, 08'th Jun 2020
Halvorsen's 13F portfolio value decreased from $21.35B to $19.21B. The number of positions decreased from 66 to 64. Viking Global increased Comcast, Fidelity Na
Editas (EDIT) Up 10.6% Since Last Earnings Report: Can It Continue?
03:31pm, Saturday, 06'th Jun 2020
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Edited Transcript of EDIT earnings conference call or presentation 7-May-20 12:00pm GMT
12:13pm, Thursday, 04'th Jun 2020
Q1 2020 Editas Medicine Inc Earnings Call
Why Editas Medicine Is Now the CRISPR Stock to Really Watch
11:02am, Wednesday, 03'rd Jun 2020
It's more than 2 1/2 times the size of Editas Medicine (NASDAQ: EDIT) and nearly four times larger than Intellia Therapeutics (NASDAQ: NTLA). While CRISPR Therapeutics and Intellia have captured in
Editas (EDIT) Moves to Buy: Rationale Behind the Upgrade
04:00pm, Friday, 29'th May 2020
Editas (EDIT) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Generation Bio tees up $125M IPO to push next-gen gene therapies
02:45pm, Tuesday, 26'th May 2020
Another preclinical-stage biotech is taking to the public markets—Generation Bio filed for a $215 million IPO to advance gene therapies for hemophilia A and phynylketonuria and push one of them into
Edited Transcript of EDIT earnings conference call or presentation 7-May-20 12:00pm GMT
02:05pm, Monday, 25'th May 2020
Q1 2020 Editas Medicine Inc Earnings Call
4 Promising Stocks to Own That You Probably Forgot About
11:28am, Saturday, 23'rd May 2020
With all the attention that COVID-19-related companies have gotten over the past couple of months, it's easy to forget that there are plenty of other promising stocks out there to invest in. While th
Xconomy: Generation Bio Leads a Trio of Biotech Companies Aiming for the Nasdaq
01:32am, Saturday, 23'rd May 2020
COVID-19 has ravaged the economy, and it was expected to quash the IPO market, too. But the biotech sector is defying the pandemic with crossover
Here's Why Editas Could Beat Intellia to a CRISPR Therapy
11:39am, Friday, 22'nd May 2020
Editas has more favorable terms for its collaborations with big pharma companies, but it still has a long way to go.
Consumer COVID-19 Tests Closer To Reality Under Mammoth Biosciences/GSK Partnership
04:00pm, Wednesday, 20'th May 2020
Mammoth Biosciences and GSK Consumer Healthcare are using CRISPR-based technology to develop an accurate, rapid and handheld test for COVID-19.
